Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Sep 21, 03:31 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Yesterday


News

Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed

MRK

DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS. “Thanks to developments in HIV science, more treatment options are becoming available to address the medical needs of people living with HIV,” said Dr. Princy Kumar, Chief, Division of Infectious Diseases and Tropical Medicine at MedStar Georgetown University Hospital and Professor of Medicine and Microbiology, Georgetown University School of Medicine, Washington, D.C. “The expanded indications offer certain people with HIV-1 infection, and their doctors, the choice to switch their current antiretroviral therapy to DELSTRIGO or PIFELTRO in combination with other antiretroviral agents.”. At Week 24, participants who switched to DELSTRIGO (doravirine/lamivudine (3TC)/tenofovir disoproxil fumarate (TDF)) on Day 1 showed statistically significant differences in changes from baseline in fasting LDL-cholesterol (LDL-C) and non-HDL-cholesterol (non-HDL-C) compared to those who continued on a boosted protease inhibitor regimen (LDL-C: -16.3 mg/dL vs. -2.6 mg/dL, treatment difference: -14.5, 95% confidence interval: -18.9, -10.1, p<0.0001; non-HDL-C: -24.8 mg/dL vs. -2.1 mg/dL, treatment difference: -22.8, 95% confidence interval: -27.9, -17.7, p<0.0001). No clinically significant drug interactions have been observed following the co-administration of doravirine and the following drugs: dolutegravir, ritonavir, TDF, 3TC, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam. For DELSTRIGO, no clinically significant drug interactions have been observed in studies conducted in healthy participants between TDF and the following medications: entecavir, methadone, oral contraceptives, sofosbuvir or tacrolimus. If DELSTRIGO (doravirine/lamivudine (3TC)/tenofovir disoproxil fumarate (TDF)) is co-administered with ledipasvir/sofosbuvir or sofosbuvir/velpatasvir, monitor for adverse reactions associated with TDF.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Wednesday, September 18


News

Bank of New York Mellon Corp Sells 861,356 Shares of Merck & Co., Inc. (NYSE:MRK) – TechNewsObserver

MRK BK

Bank of New York Mellon Corp trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. In other news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction that occurred on Friday, August 9th. The company has a market cap of $211.51 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 1.68 and a beta of 0.53. They set an “outperform” rating and a $103.00 price target for the company. Societe Generale set a $105.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Tuesday, September 3rd.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, September 17


News

Versum Materials Announces CFIUS Clearance of Merger with Merck KGaA, Darmstadt, Germany

MRK

The words “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “seek,” “should,” “forecast,” “guidance,” “outlook,” “opportunity” and similar expressions, among others, generally identify forward-looking statements, which are based on management’s reasonable expectations and assumptions as of the date the statements were made. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including without limitation the following: Merck KGaA, Darmstadt, Germany’s ability to successfully complete the proposed acquisition of Versum Materials or realize the anticipated benefits of the proposed transaction in the expected time-frames or at all; Merck KGaA, Darmstadt, Germany’s ability to successfully integrate Versum Materials’ operations into those of Merck KGaA, Darmstadt, Germany; such integration may be more difficult, time-consuming or costly than expected; the failure of any of the conditions to the proposed transaction to be satisfied; revenues following the proposed transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the proposed transaction; the retention of certain key employees at Versum Materials; risks associated with the disruption of management’s attention from ongoing business operations due to the proposed transaction; the outcome of any legal proceedings related to the proposed transaction; the impact of the proposed transaction on Versum Materials’ credit rating; the parties’ ability to meet expectations regarding the timing and completion of the proposed transaction; delays in obtaining any approvals required for the proposed transaction or an inability to obtain them on the terms proposed or on the anticipated schedule; the impact of indebtedness incurred by Merck KGaA in connection with the proposed transaction; the effects of the business combination of Versum Materials and Merck KGaA, Darmstadt, Germany, including the combined company’s future financial condition, operating results, strategy and plans; events beyond our control such as acts of terrorism; product supply versus demand imbalances in the semiconductor industry or in certain geographic markets may decrease the demand for our goods and services; our concentrated customer base; the dependence of our DS&S segment upon the capital expenditure cycles of our customers; our ability to continue technological innovation and successfully introduce new products to meet the evolving needs of our customers; our ability to protect and enforce our intellectual property rights and to avoid violating any third party intellectual property or technology rights; unexpected interruption of or shortages in our raw material supply; inability of sole source, limited source or qualified suppliers to deliver to us in a timely manner or at all; hazards associated with specialty chemical manufacturing, such as fires, explosions and accidents, could disrupt operations; increased competition and new product development by our competitors, changing customer needs and price increases in materials and components; operational, political and legal risks of our international operations; increased costs due to trade wars and the implementation of tariffs; the impact of changes in tax laws; the impact of changes in environmental and health and safety regulations, anticorruption enforcement, sanctions, import/export controls, tax and other legislation and regulations in the U.S. and other jurisdictions in which Versum Materials and its affiliates operate; our available cash and access to additional capital may be limited by substantial leverage and debt service obligations; possible liability for contamination, personal injury or third party impacts if hazardous materials are released into the environment; cyber security threats may compromise our data or disrupt our information technology applications or services; fluctuation of currency exchange rates; costs and outcomes of litigation or regulatory investigations; the timing, impact, and other uncertainties of future acquisitions or divestitures; and other risks, uncertainties and factors discussed in the company’s Form 10-Qs, Form 10-K and in the company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov or in materials incorporated therein by reference or in Merck KGaA, Darmstadt, Germany’s public reports which are available on the Merck KGaA, Darmstadt, Germany, website at www.emdgroup.com. The company assumes no obligation to update or revise any forward-looking statements. Versum Materials has annual sales of approximately US $1.4 billion, 2,300 employees and operates 14 major facilities in Asia and North America.

Read Full Details

Topics:
  • Business
  • Financial
News

FDA accepts application for Merck Ebola vaccine - MedCity News

MRK

The agency is expected to rule on the vaccine by March 14 of next year. Kenilworth, New Jersey-based Merck & Co. said Tuesday that the FDA had accepted its biologics license application for V920, a vaccine against the Ebola Zaire virus. The company noted that it has donated and shipped more than 245,000 1-milliliter doses of the investigational vaccine to the World Health Organization to address outbreaks of the virus in the Democratic Republic of the Congo and neighboring countries since May of last year, with another 190,000 ready for shipment upon request. “A top priority for us remains achieving registration of V920 and regulatory approval of our German manufacturing site so that licensed supply can be produced over time to support global public health preparedness and health security objectives,” Merck Research Laboratories Vice President Paula Annunziato said in a statement.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

Intercept Pharmaceuticals (NASDAQ:ICPT) and Merck KGaA (NASDAQ:MKGAF) Financial Survey – TechNewsObserver

MRK

Intercept Pharmaceuticals (NASDAQ:ICPT) and Merck KGaA (OTCMKTS:MKGAF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings. This table compares Intercept Pharmaceuticals and Merck KGaA’s net margins, return on equity and return on assets. This is a summary of recent ratings for Intercept Pharmaceuticals and Merck KGaA, as reported by MarketBeat.com.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, September 16


News

3 Big Stock Charts for Monday: Merck, Facebook and Microsoft

MRK FB +1 more MRK FB MSFT

The market didn’t end last week on a high note, but then again, it didn’t need to. Even with Friday’s 0.07% setback for the S&P 500, the index still mustered just a little less than a 1% advance for the five-day stretch. GE was up nearly 1% on the last day of last week, buoyed by optimism surrounding what should amount to a $5 billion debt reduction, funded by asset sales. As for names worth exploring as Monday’s action gets going, however, the stock charts of Facebook (NASDAQ:FB), Microsoft (NASDAQ:MSFT) and Merck (NYSE:MRK) are of the most interest. There’s no denying Microsoft shares have been one of the market’s best and most reliable performers for years now. Even the headwind that hammered most names late last year wasn’t horrific for MSFT stock, and shares recovered quite nicely this year from that lull. Should the Chaikin line on the weekly chart fall under zero, that may be the proverbial tipping point. As for a plausible downside target, the past two major setbacks have pulled Microsoft shares just below the 200-day moving average line, marked in white on both stock charts.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, September 15


News

Merck KGaA (FRA:MRK) PT Set at €110.00 by Bank of America – TechNewsObserver

MRK BAC

Bank of America‘s price target points to a potential upside of 11.09% from the company’s previous close. Finally, Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the company a “buy” rating in a research note on Friday, September 6th. The stock presently has a consensus rating of “Hold” and a consensus target price of €100.94 ($117.38). Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, September 13


News

Stocks - Broadcom, Merck Fall in Premarket; Amazon Rises

MRK AVGO

•Broadcom (NASDAQ:AVGO) stock fell 1.1% in premarket trade by 8:20 AM ET (12:20 GMT) after it said it was too early to predict an upturn in semiconductor demand, even though it said the market had bottomed out. The company reported earnings per share of $5.16 on $5.5 billion in revenue, roughly in line with forecasts, but said it would prioritize paying down debt over share buybacks for now. • Apple (NASDAQ:AAPL) slipped 0.4% after Goldman Sachs (NYSE:GS) lowered its price target to $165 from $187, citing concerns that its Apple TV+ free trial is likely to hurt average selling prices. •Amazon.com (NASDAQ:AMZN) stock was up 0.3% after reports that its Whole Foods grocery chain will require part-time workers to work 30 hours per week in order to get health benefits, up from the current 20 hours.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, September 11


News

The Zacks Analyst Blog Highlights: Google, Facebook, Apple, Amazon and Microsoft

MRK FB +6 more MRK FB GOOGL UTX PG MSFT KO GOOG

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Federal antitrust laws are broadly written, providing the government with the opportunity to freely apply the laws to the contemporary economic landscape. If a case does end up resulting from the federal or state level investigations, then it will take antitrust enforcement into new uncharted, digital age territory. Is something really free if online ad prices go up based on one company’s control.” The argument is that Google has used its dominance in online search to solidify its position in online advertising. Google is now facing possible litigation on the state and federal front, which continue to pose headwinds for the company and shareholders. However, in the short-term, the company has had strong estimate revisions, giving it a Zacks Rank #2 (Buy).

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Merck Shares Could Trade Sideways Before Renewed Gains

MRK

During Tuesday night's Mad Money program, Jim Cramer looked closer at drug maker Merck & Co. which had been riding high on the success of its newest cancer drug, Keytruda. Cramer said Merck is a buy, given the company's strong balance sheet and bountiful dividend yield that pays more than Treasuries. In this daily bar chart of MRK, below, we can see the recent sharp downward move in prices.

Read Full Details

Topics:
  • Business
  • Health
  • Financial